KRAS and neoplasm: Applying CRISPR‐Cas9 technology in a murine model, we found that Nf1 silencing in Kras‐mutant LUAD is associated with enhanced tumor cell viability, proliferation, endogenous tumor development, and xenograft tumor growth irrespective of p53 mutational status.